There are 2949 resources available
609O - Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Ben Tran
Session: Proffered Paper - GU, prostate
Resources:
Abstract
Slides
Webcast
611O - Abiraterone acetate plus prednisolone for hormone-naïve prostate cancer (PCa): Long-term results from metastatic (M1) patients in the STAMPEDE randomised trial (NCT00268476)
Presenter: Nicholas James
Session: Proffered Paper - GU, prostate
Resources:
Abstract
Slides
Webcast
1582O - Developing a real-world outcomes forecast model using matched oncology clinical trials and real world evidence to inform policy-making and reimbursement approaches
Presenter: Jennifer Hinkel
Session: Proffered Paper - Public Policy
Resources:
Abstract
Slides
Webcast
1583O - Clinical benefit of cancer drugs approved in Switzerland during the last decade
Presenter: Roman Adam
Session: Proffered Paper - Public Policy
Resources:
Abstract
Slides
Webcast
1584O - Health technology assessment (HTA) in England, France and Germany: What do we know about variations in cancer-related HTA outcomes?
Presenter: Ramon Schaefer
Session: Proffered Paper - Public Policy
Resources:
Abstract
Slides
Webcast
LBA51 - KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50%
Presenter: Julie Brahmer
Session: Proffered Paper - NSCLC metastatic 2
Resources:
Abstract
Slides
Webcast
LBA52 - EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%
Presenter: Ahmet Sezer
Session: Proffered Paper - NSCLC metastatic 2
Resources:
Abstract
Slides
Webcast
LBA53 - Precision immuno-oncology for advanced non-small cell lung cancer (NSCLC) patients (pts) treated with PD1/L1 immune checkpoint inhibitors (ICIs): A first analysis of the PIONeeR study
Presenter: Fabrice Barlesi
Session: Proffered Paper - NSCLC metastatic 2
Resources:
Abstract
Slides
Webcast
LBA54 - Randomized phase III trial of nivolumab in combination with carboplatin, paclitaxel, and bevacizumab as first-line treatment for patients with advanced or recurrent non-squamous NSCLC
Presenter: Jong-Seok Lee
Session: Proffered Paper - NSCLC metastatic 2
Resources:
Abstract
Slides
Webcast
LBA55 - WJOG @Be study: A phase II study of atezolizumab (atez) with bevacizumab (bev) for non-squamous (sq) non-small cell lung cancer (NSCLC) with high PD-L1 expression
Presenter: Takashi Seto
Session: Proffered Paper - NSCLC metastatic 2
Resources:
Abstract
Slides
Webcast